Which one is stronger, alectinib or ositinib, needs to be chosen by a specialist according to the condition. It is used for the treatment of advanced non-small cell lung cancer patients who have progressed on EGFR-TKI therapy and are T 790M positive, and it is a third-generation EGFR-targeted drug.
Aimitinib is used in the second line for the treatment of EGFR T790M-positive advanced non-small cell lung cancer. Both drugs have their own advantages and disadvantages, and the common adverse effects of Aimitinib are rash, itching, stomatitis, eye and accessory organ diseases such as macular degeneration, corneal detachment, dry eye, etc., musculoskeletal and joint pain, and cardiac arrhythmia. Contraindications: prohibited for those who are allergic to alectinib.
Oxitinib is used for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer positive for the EGFR T790 mutation. Adverse reactions include onset of cardiomyopathy, venous thromboembolism, pneumonitis, pulmonary embolism, pain in musculoskeletal system, skin rashes, dry eyes, neurological system such as cerebral hemorrhage, cerebral infarction, diarrhea, nausea, and loss of appetite, etc., and is contraindicated in those who are allergic to oxitinib.
Ameditinib and Oxitinib, it is recommended to apply under the guidance of a doctor, do not self-medication, if you are not feeling well, consult a doctor in time.